MyFinsight
Home
Blog
About
Proceeds from 2025 credit
facility
$299.504M
Amortization expense
$62.953M
(-43.26%↓ Y/Y)
Stock-based compensation
expense
$14.484M
(-35.17%↓ Y/Y)
Proceeds from the
exercise of stock options
$0.481M
(-74.14%↓ Y/Y)
Accrued liabilities
$12.275M
(201.56%↑ Y/Y)
Accrued rebates,
returns and discounts
$7.878M
(195.62%↑ Y/Y)
Accounts receivable
-$2.129M
(86.27%↑ Y/Y)
Depreciation expense
$1.812M
(-18.60%↓ Y/Y)
Non-cash interest
expense for...
$1.082M
(-60.25%↓ Y/Y)
Accounts payable
$0.317M
(-95.44%↓ Y/Y)
Net cash provided by
(used in) financing...
$292.089M
(496.83%↑ Y/Y)
Net cash provided by
operating activities
$71.323M
(-44.21%↓ Y/Y)
Canceled cashflow
$7.896M
Canceled cashflow
$31.536M
Product revenues, net
$199.878M
(-45.35%↓ Y/Y)
Interest income
$2.289M
Net (decrease)
increase in cash, cash...
-$139.179M
(-434.28%↓ Y/Y)
Canceled cashflow
$363.412M
Sales of marketable
securities
$151.805M
Maturities of marketable
securities
$3.494M
(-88.64%↓ Y/Y)
Repayment of term notes
$7.25M
(-77.55%↓ Y/Y)
Payments made for
employee stock tax...
$0.646M
(-94.14%↓ Y/Y)
Net (loss) income
-$15.051M
(-204.52%↓ Y/Y)
Prepaid expenses and
other assets
$8.232M
(-61.02%↓ Y/Y)
Deferred income taxes
-$7.155M
(-107.21%↓ Y/Y)
Inventory
$0.597M
(-76.93%↓ Y/Y)
Net (amortization)
accretion for deferred...
-$0.206M
Deferred revenue
-$0.166M
Non-cash lease benefit
-$0.084M
(-40.00%↓ Y/Y)
Net amortization of
premiums and discounts on...
$0.045M
(-92.35%↓ Y/Y)
Canceled cashflow
$202.167M
Net cash used in
investing activities
-$502.591M
(-3890.40%↓ Y/Y)
Canceled cashflow
$155.299M
Intangible asset
amortization
$62.953M
Commercial expenses
$46.403M
(-45.35%↓ Y/Y)
Cost of product
revenues (excluding...
$26.633M
(-45.76%↓ Y/Y)
Other segment items
$25.48M
(928.66%↑ Y/Y)
Interest expense
$19.519M
(-52.68%↓ Y/Y)
Stock-based compensation
expense
$14.484M
(-35.17%↓ Y/Y)
Corporate expenses
$12.163M
(-47.32%↓ Y/Y)
Medical expenses
$7.899M
(-50.21%↓ Y/Y)
Provision for income taxes
$1.519M
(-73.57%↓ Y/Y)
Technical operations
expenses
$0.165M
(-29.49%↓ Y/Y)
Acquisition of azstarys (net
of cash acquired)
$655.403M
Purchases of marketable
securities
$1.991M
(-95.32%↓ Y/Y)
Purchases of property and
equipment
$0.496M
(-42.53%↓ Y/Y)
Back
Back
Cash Flow
COLLEGIUM PHARMACEUTICAL, INC (COLL)
COLLEGIUM PHARMACEUTICAL, INC (COLL)
source: myfinsight.com